Prasterone enanthate

Prasterone enanthate
Clinical data
Trade names	Gynodian Depot (with estradiol valerate)
Other names	DHEA enanthate; Prasterone heptanoate; DHEA heptanoate; DHEA-E; EDHEA; SH-70833 (with EVTooltip estradiol valerate); Androst-5-en-3β-ol-17-one 3β-heptanoate
Routes of; administration	Intramuscular injection
Drug class	Androgen; Anabolic steroid; Androgen ester; Estrogen; Neurosteroid
ATC code	G03EA03 (WHO) ;
Legal status
Legal status	In general: ℞ (Prescription only);
Pharmacokinetic data
Duration of action	18 days
Identifiers
	IUPAC name [(3S,8R,9S,10R,13S,14S)-10,13-Dimethyl-17-oxo-1,2,3,4,7,8,9,11,12,14,15,16-dodecahydrocyclopenta[a]phenanthren-3-yl] heptanoate;
CAS Number	23983-43-9;
PubChem CID	163331;
ChemSpider	143333;
UNII	2W8I1S6T5L;
CompTox Dashboard (EPA)	DTXSID00946833 ;
ECHA InfoCard	100.041.777
Chemical and physical data
Formula	C26H40O3
Molar mass	400.603 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CCCCCCC(=O)O[C@H]1CC[C@@]2([C@H]3CC[C@]4([C@H]([C@@H]3CC=C2C1)CCC4=O)C)C;
	InChI InChI=1S/C26H40O3/c1-4-5-6-7-8-24(28)29-19-13-15-25(2)18(17-19)9-10-20-21-11-12-23(27)26(21,3)16-14-22(20)25/h9,19-22H,4-8,10-17H2,1-3H3/t19-,20-,21-,22-,25-,26-/m0/s1; Key:HHENOUDBWKNPAB-BNCSLUSBSA-N;

Prasterone enanthate (also known as prasterone heptanoate, dehydroepiandrosterone enanthate, DHEA enanthate, DHEA-E, or androst-5-en-3β-ol-17-one 3β-heptanoate) is a synthetic, injected, long-lasting ester prodrug^[1] of dehydroepiandrosterone (DHEA), a weak androgen and neurosteroid.^[2]^[3]^[4] It is a component of Gynodian Depot, a combination formulation of 4 mg estradiol valerate and 200 mg prasterone enanthate in oil for depot intramuscular injection that is used in the treatment of menopausal symptoms and is marketed in Europe and South America.^[5]^[6]^[7]^[8]^[9]^[10] Prasterone enanthate has an average duration of 18 days in this formulation.^[1] The pharmacokinetics of the formulation have also been assessed in other studies.^[1] The drug was patented, by Schering, in 1971.^[3]

References

^ ^a ^b ^c ^d Düsterberg B, Wendt H (1983). "Plasma levels of dehydroepiandrosterone and 17 beta-estradiol after intramuscular administration of Gynodian-Depot in 3 women". Horm. Res. 17 (2): 84–9. PMID 6220949.
^ J. Elks (14 November 2014). The Dictionary of Drugs: Chemical Data: Chemical Data, Structures and Bibliographies. Springer. pp. 641–. ISBN 978-1-4757-2085-3.
^ ^a ^b William Andrew Publishing (22 October 2013). Pharmaceutical Manufacturing Encyclopedia, 3rd Edition. Elsevier. pp. 1208–. ISBN 978-0-8155-1856-3.
^ John W. Blunt; Murray H. G. Munro (19 September 2007). Dictionary of Marine Natural Products with CD-ROM. CRC Press. pp. 1075–. ISBN 978-0-8493-8217-8.
^ https://www.drugs.com/international/gynodian-depot.html
^ J. Horsky; J. Presl (6 December 2012). Ovarian Function and its Disorders: Diagnosis and Therapy. Springer Science & Business Media. pp. 146–. ISBN 978-94-009-8195-9.
^ D. Platt (6 December 2012). Geriatrics 3: Gynecology · Orthopaedics · Anesthesiology · Surgery · Otorhinolaryngology · Ophthalmology · Dermatology. Springer Science & Business Media. pp. 6–. ISBN 978-3-642-68976-5.
^ S. Campbell (6 December 2012). The Management of the Menopause & Post-Menopausal Years: The Proceedings of the International Symposium held in London 24–26 November 1975 Arranged by the Institute of Obstetrics and Gynaecology, The University of London. Springer Science & Business Media. pp. 395–. ISBN 978-94-011-6165-7.
^ Carrie Bagatell; William J. Bremner (27 May 2003). Androgens in Health and Disease. Springer Science & Business Media. pp. 277–. ISBN 978-1-59259-388-0.
^ Frigo P, Eppel W, Asseryanis E, Sator M, Golaszewski T, Gruber D, Lang C, Huber J (1995). "The effects of hormone substitution in depot form on the uterus in a group of 50 perimenopausal women--a vaginosonographic study". Maturitas. 21 (3): 221–5. PMID 7616871.

[pmid6220949-1] Düsterberg B, Wendt H (1983). "Plasma levels of dehydroepiandrosterone and 17 beta-estradiol after intramuscular administration of Gynodian-Depot in 3 women". Horm. Res. 17 (2): 84–9. PMID 6220949.

[Elks2014-2] J. Elks (14 November 2014). The Dictionary of Drugs: Chemical Data: Chemical Data, Structures and Bibliographies. Springer. pp. 641–. ISBN 978-1-4757-2085-3.

[Publishing2013-3] William Andrew Publishing (22 October 2013). Pharmaceutical Manufacturing Encyclopedia, 3rd Edition. Elsevier. pp. 1208–. ISBN 978-0-8155-1856-3.

[BluntMunro2007-4] John W. Blunt; Murray H. G. Munro (19 September 2007). Dictionary of Marine Natural Products with CD-ROM. CRC Press. pp. 1075–. ISBN 978-0-8493-8217-8.

[Drugs.com-5] ttps://www.drugs.com/international/gynodian-depot.html

[HorskyPresl2012-6] J. Horsky; J. Presl (6 December 2012). Ovarian Function and its Disorders: Diagnosis and Therapy. Springer Science & Business Media. pp. 146–. ISBN 978-94-009-8195-9.

[Platt2012-7] D. Platt (6 December 2012). Geriatrics 3: Gynecology · Orthopaedics · Anesthesiology · Surgery · Otorhinolaryngology · Ophthalmology · Dermatology. Springer Science & Business Media. pp. 6–. ISBN 978-3-642-68976-5.

[Campbell2012-8] S. Campbell (6 December 2012). The Management of the Menopause & Post-Menopausal Years: The Proceedings of the International Symposium held in London 24–26 November 1975 Arranged by the Institute of Obstetrics and Gynaecology, The University of London. Springer Science & Business Media. pp. 395–. ISBN 978-94-011-6165-7.

[BagatellBremner2003-9] Carrie Bagatell; William J. Bremner (27 May 2003). Androgens in Health and Disease. Springer Science & Business Media. pp. 277–. ISBN 978-1-59259-388-0.

[pmid7616871-10] Frigo P, Eppel W, Asseryanis E, Sator M, Golaszewski T, Gruber D, Lang C, Huber J (1995). "The effects of hormone substitution in depot form on the uterus in a group of 50 perimenopausal women--a vaginosonographic study". Maturitas. 21 (3): 221–5. PMID 7616871.

[1]

[2]

[3]

[4]

[5]

[6]

[7]

[8]

[9]

[10]

See also

References